WO2004018621A2 - Method for determining gene knockout strategies - Google Patents

Method for determining gene knockout strategies Download PDF

Info

Publication number
WO2004018621A2
WO2004018621A2 PCT/US2003/021598 US0321598W WO2004018621A2 WO 2004018621 A2 WO2004018621 A2 WO 2004018621A2 US 0321598 W US0321598 W US 0321598W WO 2004018621 A2 WO2004018621 A2 WO 2004018621A2
Authority
WO
WIPO (PCT)
Prior art keywords
objective
candidate
optimization problem
metabolic
cellular
Prior art date
Application number
PCT/US2003/021598
Other languages
French (fr)
Other versions
WO2004018621A3 (en
Inventor
Costas D. Maranas
Anthony R. Burgard
Priti Pharkya
Original Assignee
The Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Penn State Research Foundation filed Critical The Penn State Research Foundation
Priority to EP03792962A priority Critical patent/EP1532516A4/en
Priority to JP2005501742A priority patent/JP4418793B2/en
Priority to CA002491753A priority patent/CA2491753A1/en
Priority to AU2003256480A priority patent/AU2003256480B2/en
Publication of WO2004018621A2 publication Critical patent/WO2004018621A2/en
Publication of WO2004018621A3 publication Critical patent/WO2004018621A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for determining candidates for gene deletions and additions using a model of a metabolic network associated with an organism, the model includes a plurality of metabolic reactions defining metabolite relationships, the method includes selecting a bioengineering objective for the organism, selecting at least one cellular objective, forming an optimization problem that couples the at least one cellular objective with the bioengineering objective, and solving the optimization problem to yield at least one candidate.

Description

TITLE: METHOD FOR DETERMINING GENE KNOCKOUT STRATEGIES
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is based on U.S. Patent Application Serial No. 60/395,763, filed July 10, 2002; U.S. Patent Application Serial No. 60/417,511, filed October, 9, 2002, and U.S. Patent Application Serial No. 60/444,933, filed February 3, 2003, each of which is herein incorporated by reference in its entirety.
GRANT REFERENCE This work has been supported by Department of Energy pursuant to Grant No.
58855 and the National Science Foundation Grant No. BES0120277. Accordingly, the U.S. government may have certain rights in the invention.
BACKGROUND OF THE INVENTION The systematic development of engineered microbial strains for optimizing the production of chemicals or biochemicals is an overarching challenge in biotechnology (Stephanopoulos et al., 1998). However, in the absence of metabolic and genetic engineering interventions, the product yields of many microorganisms are often far below their theoretical maximums. This is expected because cellular metabolism is primed, through natural selection, for the maximum responsiveness to the history of selective pressures rather than for the ove roduction of specific chemical compounds. Not surprisingly, the behavior of metabolic networks is governed by internal cellular objectives which are often in direct competition with chemical overproduction targets.
The recent explosion of annotated sequence information along with a wealth of chemical literature has enabled the reconstruction of genome-scale metabolic networks for many microorganisms (Edwards andPalsson, 2000; Schilling and Palsson, 2000; Schilling et al., 2002; Forster et al., 2003). This information, used in the context of the flux balance analysis (FBA) modeling framework (Varma and Palsson, 1993), has been employed extensively to explore the integrated functions of metabolic networks (Burgard and Maranas, 2001; Burgard et al., 2001; Papin et al., 2003; Price et al., 2003). FBA models typically invoke the optimization of a particular cellular objective (e.g., ATP production (Majewski and Domach, 1990; Ramakrishna et al., 2001), biomass formation (Varma and Palsson, 1993,1994), minimization of metabolic adjustment (Segre et al., 2002)), subject to network stoichiometry, to suggest a likely flux distribution. Stoichiometric models of Escherichia coli (E. coli) metabolism utilizing the biomass maximization hypothesis have been in some cases successful at (i) predicting the lethality of gene knockouts (Edwards and Palsson, 2000; Badarinarayana et al., 2001), (ii) identifying the correct sequence of byproduct secretion under increasingly anaerobic conditions (Varma et al., 1993), and (iii) quantitatively predicting cellular growth rates under certain conditions (Edwards et al., 2001). Interestingly, recent work suggests that even when FBA predictions under the biomass maximization assumption seem to fail, metabolic networks can be evolved, for certain cases, towards maximum growth (i.e., biomass yield) through adaptive evolution (Ibarra et al., 2002).
The ability to investigate the metabolism of single-cellular organisms at a genomic scale, and thus systemic level, motivates the need for novel computational methods aimed at identifying strain engineering strategies.
Thus, one object, feature, or advantage of the present invention is to provide a method for computationally suggesting the manner in which to achieve bioengineering objectives.
A further object, feature or advantage of the present invention is to determine candidates for gene deletion or addition through use of a model of a metabolic network.
A still further object, feature or advantage of the present invention is to provide an optimized method for computationally achieving a bioengineering objective.
Yet another object, feature or advantage of the present invention is to provide an optimized method for computationally achieving a bioengineering objective that is robust. One or more of these and/or other objects, features and advantages of the present invention will become apparent after review of the following detailed description of the disclosed embodiments and the appended claims.
BRIEF SUMMARY OF THE INVENTION The systematic development of engineered microbial strains for optimizing the production of chemical or biochemicals is an overarching challenge in biotechnology. The advent of genome-scale models of metabolism has laid the foundation for the development of computational procedures for suggesting genetic manipulations that lead to overproduction. The present invention describes a computational framework for suggesting gene deletion strategies leading to the overproduction of chemicals or biochemicals in E.coli. This is accomplished by ensuring that a drain towards growth resources (i.e., carbon, redox potential, and energy) is accompanied, due to stoichiometry, by the production of a desired production. Specifically, the computation framework identifies multiple gene deletion combinations that maximally couple a postulated cellular objective (e.g., biomass formation) with externally imposed chemical production targets. This nested structure gives rise to a bilevel optimization problems which are solved based on a transformation inspired by duality theory. This procedure of this framework, by coupling biomass formation with chemical production, suggest a growth selection/adaption system for indirectly evolving overproducing mutants.
One embodiment of the invention is directed to a method for determining candidates for gene deletions and additions. The method uses a model of a metabolic network associated with an organism. The model includes a number of metabolic reactions defining metabolite relationships. The method includes selecting a bioengineering objective for the selecting the organism. Next, at least one cellular objective is selected. An optimization problem is formed that couples the cellular objective with the bioengineering objective. Finally, the optimization problem is solved to yield at least one candidate.
BRIEF DESCRIPTION OF THE DRAWTNGS
Figure 1 depicts the bilevel optimization structure of Optknock. The inner problem performs the flux allocation based on the optimization of a particular cellular objective (e.g., maximization of biomass yield, MOMA). The outer problem then maximizes the bioengineering objective (e.g., chemical production) by restricting access to key reactions available to the optimization of the inner problem.
Figure 2 depicts the flux distributions of the (A) wild-type E. coli, (B) succinate mutant B, (C) succinate mutant C, and (D) lactate mutant C networks that maximize biomass yield under anaerobic conditions. Figure 3 shows (A) succinate or (B) lactate production limits under anaerobic conditions for mutant A (dash/dotted line), mutant B (dotted line), mutant C (short dashes) and the wild-type E. coli network (solid). The production limits are obtained by separately maximizing and minimizing succinate or lactate production for the biomass yields available to each network. The yellow points depict the solution identified by OptKnock (i.e., maximum chemical production at the maximum biomass yield).
Figure 4 shows the aerobic flux distributions of the (A) wild-type E. coli, (B) mutant A, and (C) mutant B networks that maximize biomass yield. Results for mutants A and B assume the reactions responsible for 1,3-propanediol production are available. Figure 5 shows 1,3-propanediol (PDO) production limits under aerobic conditions for mutant A (dash/dotted line), mutant B (dotted line), and the wild-type E. coli network (solid). The yellow points depict the solution identified by OptKnock (i.e., maximum chemical production at the maximum biomass yield).
Figure 6 shows projection of the multidimensional flux space onto two dimensions. The pink region represents flux ranges potentially reachable by both the mutant and complete networks, while the blue region corresponds to flux distributions rendered unreachable by the gene deletion(s). Point A represents the maximum biomass yield solution. Point B is the solution assuming the minimization of metabolic adjustment hypothesis for the mutant network, while point C is the solution assuming the mutant network will maximize its biomass yield.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The ability to investigate the metabolism of single-cellular organisms at a genomic scale, and thus systemic level, motivates the need for novel computational methods aimed at identifying strain engineering strategies. The present invention includes a computational framework termed OptKnock for suggesting gene deletion strategies leading to the overproduction of specific chemical compounds inE. coli. This is accomplished by ensuring that the production of the desired chemical becomes an obligatory byproduct of growth by "shaping" the connectivity of the metabolic network, hi other words, OptKnock identifies and subsequently removes metabolic reactions that are capable of uncoupling cellular growth from chemical production. The computational procedure is designed to identify not just straightforward but also non-intuitive knockout strategies by simultaneously considering the entire E. coli metabolic network as abstracted in the in silico E. coli model of Palsson and co workers (Edwards and Palsson, 2000). The complexity and built-in redundancy of this network (e.g., the E. coli model encompasses 720 reactions) necessitates a systematic and efficient search approach to combat the combinatorial explosion of candidate gene knockout strategies.
The nested optimization framework shown in Figure 1 is developed to identify multiple gene deletion combinations that maximally couple cellular growth objectives with externally imposed chemical production targets. This multi-layered optimization structure involving two competing optimal strategists (i.e., cellular objective and chemical production) is referred to as a bilevel optimization problem (Bard, 1998). Problem formulation specifics along with an elegant solution procedure drawing upon linear programming (LP) duality theory are described in the Methods section. The OptKnock procedure is applied to succinate, lactate, and 1,3-propanediol (PDO) production in E. coli with the maximization of the biomass yield for a fixed amount of uptaken glucose employed as the cellular objective. The obtained results are also contrasted against using the minimization of metabolic adjustment (MOMA) (Segre et al., 2002) as the cellular objective. Based on the OptKnock framework, it is possible identify the most promising gene knockout strategies and their corresponding allowable envelopes of chemical versus biomass production in the context of succinate, lactate, and PDO production in E. coli. A preferred embodiment of this invention describes a computational framework, termed OptKnock, for suggesting gene deletions strategies that could lead to chemical production in E. coli by ensuring that the drain towards metabolites/compounds necessary for growth resources (i.e., carbons, redox potential, and energy) must be accompanied, due to stoichiometry, by the production of the desired chemical. Therefore, the production of the desired product becomes an obligatory byproduct of cellular growth. Specifically, OptKnock pinpoints which reactions to remove from a metabolic network, which can be realized by deleting the gene(s) associated with the identified functionality. The procedure was demonstrated based on succinate, lactate, and PDO production in E. coli K-12. The obtained results exhibit good agreement with strains pubHshed in the literature. While some of the suggested gene deletions are quite straightforward, as they essentially prune reaction pathways competing with the desired one, many others are at first quite non- intuitive reflecting the complexity and built-in redundancy of the metabolic network of E. coli. For the succinate case, OptKnock correctly suggested anaerobic fermentation and the removal of the phosphotranferase glucose uptake mechanism as a consequence of the competition between the cellular and chemical production objectives, and not as a direct input to the problem, hi the lactate study, the glucokinase-based glucose uptake mechanism was shown to decouple lactate and biomass production for certain knockout strategies. For the PDO case, results show that the Εntner-Doudoroff pathway is more advantageous than ΕMP glycolysis despite the fact that it is substantially less energetically efficient, addition, the so far popular tpi knockout was clearly shown to reduce the maximum yields of PDO while a complex network of 15 reactions was shown to be theoretically possible of "leaking" flux from the PPP pathway to the TCA cycle and thus decoupling PDO production from biomass formation. The obtained results also appeared to be quite robust with respect to the choice for the cellular objective. The present invention contemplates any number of cellular objectives, including but not limited to maximizing a growth rate, maximizing ATP production, minimizing metabolic adjustment, minimizing nutrient uptake, minimizing redox production, minimizing a Euclidean norm, and combinations of these and other cellular objectives.
It is important to note that the suggested gene deletion strategies must be interpreted carefully. For example, in many cases the deletion of a gene in one branch of a branched pathway is equivalent with the significant up-regulation in the other. In addition, inspection of the flux changes before and after the gene deletions provides insight as to which genes need to be up or down-regulated. Lastly, the problem of mapping the set of identified reactions targeted for removal to its corresponding gene counterpart is not always uniquely specified. Therefore, careful identification of the most economical gene set accounting for isozymes and multifunctional enzymes needs to be made.
Preferably, in the OptKnock framework, the substrate uptake flux (i.e., glucose) is assumed to be 10 mmol/gDW-hr. Therefore, all reported chemical production and biomass formation values are based upon this postulated and not predicted uptake scenario. Thus, it is quite possible that the suggested deletion mutants may involve substantially lower uptake efficiencies. However, because OptKnock essentially suggests mutants with coupled growth and chemical production, one could envision a growth selection system that will successively evolve mutants with improved uptake efficiencies and thus enhanced desired chemical production characteristics.
Where there is a lack of any regulatory or kinetic information within the purely stoichiometric representation of the inner opthnization problem that performs flux allocation, OptKnock is used to identify any gene deletions as the sole mechanism for chemical overproduction. Clearly, the lack of any regulatory or kinetic information in the model is a simplification that may in some cases suggest unreahstic flux distributions. The incorporation of regulatory information will not only enhance the quality of the suggested gene deletions by more appropriately resolving flux allocation, but also allow us to suggest regulatory modifications along with gene deletions as mechanisms for strain improvement. The use of alternate modeling approaches (e.g., cybernetic (Kompala et al, 1984; Ramakrishna et al., 1996; Varner and Ramkrishna, 1999), metabolic control analysis (Kacser and Burns, 1973; Heinrich and Rapoport, 1974; Hatzimanikatis et al., 1998)), if available, can be incorporated within the OptKnock framework to more accurately estimate the metabolic flux distributions of gene-deleted metabolic networks. Nevertheless, even without such regulatory or kinetic information, OptKnock provides useful suggestions for strain improvement and more importantly establishes a systematic framework. The present invention naturally contemplates future improvements in metabolic and regulatory modeling frameworks.
Methods
The maximization of a cellular objective quantified as an aggregate reaction flux for a steady state metabolic network comprising a set f= {1,..., N} ofmetabolites and a set* = {1,..., M) of metabolic reactions fueled by a glucose substrate is expressed mathematically as follows,
maximize vcellular objective (Primal)
M subject to ^T SyV • = 0, V i e V Vμt8 + vglc_lψtake mmol/gDW'hr
Vatp ≥ Vatp_main mmol/gDW-hr
"> ,t ΑTSet t /t vbiomass ≤ ^biomass i, "
Figure imgf000009_0001
V < 0, Vy 6 - ^ecr_only
v e ^ V / e ^ev where Sy is the stoichiometric coefficient of metabolite i in reaction./', v,- represents the flux of reaction./, vglc upiake is the basis glucose uptake scenario, vatp_main is the non-growth associated ATP maintenance requirement, and v^t ^ss is a nήnimum level of biomass production. The vector v includes both internal and transport reactions. The forward (i.e., positive) direction of transport fluxes corresponds to the uptake of a particular metabolite, whereas the reverse (i.e., negative) direction corresponds to metabolite secretion. The uptake of glucose through the phosphotransferase system and glucokinase are denoted by vpts and vgik, respectively. Transport fluxes for metabolites that can only be secreted from the network are members of «/ ecr_oniy Note also that the complete set of reactions « is subdivided into reversible M^ and irreversible Ji\πSw reactions. The cellular obj ective is often assumed to be a drain of biosynthetic precursors in the ratios required for biomass formation (Neidhardt and Curtiss, 1996). The fluxes are reported per 1 gDW-hr such that biomass formation is expressed as g biomass produced/ gDW-hr or lfhr. The modeling of gene deletions, and thus reaction elimination, first requires the incorporation of binary variables into the flux balance analysis framework (Burgard and Maranas, 2001; Burgard et al, 2001). These binary variables, r j if reaction flux vj is active y t = \ -^ . • ■ , Vj e J£
J [0 if reaction flux vj is not active
assume a value of one if reaction j is active and a value of zero if it is inactive. The following constraint,
Figure imgf000009_0002
ensures that reaction flux v,- is set to zero only if variable yj is equal to zero. Alternatively, when yj is equal to one, v,- is free to assume any value between a lower v/"n and an upper / mflX bound. In this study, vj"1" and vj,ax are identified by minimizing and subsequently maximizing every reaction flux subject to the constraints from the Primal problem. The identification of optimal gene/reaction knockouts requires the solution of a bilevel optimization problem that chooses the set of reactions that can be accessed (yj = 1) so as the optimization of the cellular objective indirectly leads to the overproduction of the chemical or biochemical of interest (see also Figure 1). Using biomass formation as the cellular objective, this is expressed mathematically as the following bilevel mixed-integer optimization problem maximize V chemical (OptKnock)
Figure imgf000010_0001
subject to /"max:mrze
subject to
Figure imgf000010_0002
Vj^ - yj ≤ vj ≤ v^ - yj , V/ e .
# = {0,1}, \fj & t
∑(i-yj) ≤ κ jcM
where K is the number of allowable knockouts. The final constraint ensures that the resulting network meets a minimum biomass yield, vb'ζ^s .
The direct solution of this two-stage optimization problem is intractable given the high dimensionality of the flux space (i.e., over 700 reactions) and the presence of two nested optimization problems. To remedy this, we develop an efficient solution approach borrowing from LP duality theory which shows that for every linear programming problem (primal) there exists a unique optimization problem (dual) whose optimal objective value is equal to that of the primal problem. A similar strategy was employed by (Burgard and Maranas, 2003) for identifying/testing metabolic objective functions from metabolic flux data. The dual problem (Ignizio and Cavalier, 1994) associated with the OptKnock inner problem is
minimize vatp_mam ^t + vb'∑* -/ iass +vslc_uptake Sl (Dual)
subject to ∑ λ chSiιglk + μglk + glc = 0
toich$i,Pts + μPts + gic = o
N i i,biomass r1 biomass i=l
N λ oichSy + μj = 0, Vj e J, j ≠ glk, pts, biomass i=l
μ 0- - yj ) j ≤ μ - -yj ' v G -**> Αnάi -* *-<«&*
μ . ≥ μ™ (1 - v j ) , V j ε ev and - ecr_oniy
μ} ≤ μ™ (1 - y), Vy e « τev and j £ - ecr_oniy
μj e S Vy e M^^ and t ecr_oniy
Figure imgf000011_0001
glc e -5£ where χfm h is the dual variable associated with the stoichiometric constraints, glc is the dual variable associated with the glucose uptake constraint, and μj is the dual variable associated with any other restrictions on its corresponding flux v,- in the Primal. Note that the dual variable μj acquires unrestricted sign if its corresponding flux in the OptKnock inner problem is set to zero by enforcing = 0. The parameters μfun and μ/ max are identified by minimizing and subsequently maximizing their values subject to the constraints of the Dual problem.
If the optimal solutions to the Primal and Dual problems are bounded, their objective function values must be equal to one another at optimality. This means that every optimal solution to both problems can be characterized by setting their objectives equal to one another and accumulating their respective constraints. Thus the bilevel formulation for OptKnock shown previously can be transformed into the following single-level MJLP maximize vchemicai (OptKnock) subject to
Figure imgf000012_0001
' biomass ~*~v gic_uptake ' S'c
M
∑SyVj=0, Vie
7=1
Vpts + Vgik^ Vglc_uptake mmol/gDW'hr
Vatp ≥ Vatp nain mmol/gDW-hr
∑^hhSi,glkglk+glc = 0 i=l
oichSi,ptspts+glc = 0
Σ TStoich rt , _ ι i i,b mass M biomass i=l
N
∑ λf°'c 'Sy + μj = 0 , V / e t>, j ≠ glk, pts, biomass i=l
Figure imgf000012_0002
vbιomass - v biomass μf (i - yj fj T - Q--yj) > v e -* and / * A** ™
μj ≥ μf" - (l - yj , Vj e ev and -/ cr_oniy
/, < .J" (1 - J> ; ) » Vj 6 Λ&πev andj £ - cr_only
Figure imgf000013_0001
0fcΛ e Rf Vj e f
glc e 8fo
# = {0,1}, Vj J
An important feature of the above formulation is that if the problem is feasible, the optimal solution will always be found. In this invention, the candidates for gene knockouts included, but are not limited to, all reactions of glycolysis, the TCA cycle, the pentose phosphate pathway, respiration, and all anaplerotic reactions. This is accomplished by limiting the number of reactions included in the summation (i.e., ∑ - J^) = -O- jeCentral Metabolism Problems containing as many as 100 binary variables were solved in the order of minutes to hours using CPLEX 7.0 accessed via the GAMS modeling environment on an IBM RS 6000-270 workstation. It should be understood, however, that the present invention is not dependent upon any particular type of computer or environment being used. Any type can be used to allow for inputting and outputting the information associated with the methodology of the present invention. Moreover, the steps of the methods of the present invention can be implemented in any number of types software applications, or languages, and the present invention is not limited in this respect.
It will be appreciated that other embodiments and uses will be apparent to those skilled in the art and that the invention is not limited to these specific illustrative examples. EXAMPLE 1 Succinate and Lactate Production Which reactions, if any, that could be removed from the E. coli K-12 stoichiometric model (Edwards and Palsson, 2000) so as the remaining network produces succinate or lactate whenever biomass maximization is a good descriptor of flux allocation were identified. A prespecified amount of glucose (10 mmol/gDW-hr), along with unconstrained uptake routes for inorganic phosphate, oxygen, sulfate, and ammonia are provided to fuel the metabolic network. The optimization step could opt for or against the phosphotransferase system, glucokinase, or both mechanisms for the uptake of glucose. Secretion routes for acetate, carbon dioxide, ethanol, formate, lactate and succinate are also enabled. Note that because the glucose uptake rate is fixed, the biomass and product yields are essentially equivalent to the rates of biomass and product production, respectively. In all cases, the OptKnock procedure eliminated the oxygen uptake reaction pointing at anaerobic growth conditions consistent with current succinate (Zeikus et al., 1999) and lactate (Datta et al., 1995) fermentative production strategies.
Table I summarizes three of the identified gene knockout strategies for succinate overproduction {i.e., mutants A, B, and C). The anaerobic flux distributions at the maximum biomass yields for the complete E. coli network (i.e., wild-type), mutant B, and mutant C are illustrated in Figure 2A-C. The results for mutant A suggested that the removal of two reactions (i.e., pyruvate formate lyase and lactate dehydrogenase) from the network results in succinate production reaching 63% of its theoretical maximum at the maximum biomass yield. This knockout strategy is identical to the one employed by Stols and Donnelly (Stols and Donnelly, 1997) in their succinate overproducing E. coli strain. Next, the envelope of allowable succinate versus biomass production was explored for the wild-type E. coli network and the three mutants listed in Table I. Note that the succinate production limits, shown in Figure 3 A, revealed that mutant A does not exhibit coupled succinate and biomass formation until the yield of biomass approaches 80% of the maximum. Mutant B, however, with the additional deletion of acetaldehyde dehydrogenase, resulted in a much earlier coupling of succinate with biomass yields. A less intuitive strategy was identified for mutant C which focused on inactivating two PEP consuming reactions rather than eliminating competing byproduct (i.e., ethanol, formate, and lactate) production mechanisms. First, the phosphotransferase system was disabled requiring the network to rely exclusively on glucokinase for the uptake of glucose. Next, pyruvate kinase was removed leaving PEP carboxykinase as the only central metabolic reaction capable of draining the significant amount of PEP supplied by glycolysis. This strategy, assuming that the maximum biomass yield could be attained, resulted in a succinate yield approaching 88% of the theoretical maximum. In addition, Figure 3 A revealed significant succinate production for every attainable biomass yield, while the maximum theoretical yield of succinate is the same as that for the wild-type strain. The OptKnock framework was next applied to identify knockout strategies for coupling lactate and biomass production. Table I shows three of the identified gene knockout strategies {i.e., mutants A, B, and C) and the flux distribution of mutant C at the maximum biomass yield is shown in Figure 2D. Mutant A redirects flux toward lactate at the maximum biomass yield by blocking acetate and ethanol production. This result is consistent with previous work demonstrating that an adh, pta mutant E. coli strain could grow anaerobically on glucose by producing lactate (Gupta and Clark, 1989). Mutant B provides an alternate strategy involving the removal of an initial glycolysis reaction along with the acetate production mechanism. This results in a lactate yield of 90% of its theoretical limit at the maximum biomass yield. The vertical red line for mutant B in Figure 3B indicates that the network could avoid producing lactate while maximizing biomass formation. This is due to the fact that OptKnock does not explicitly account for the "worst-case" alternate solution. It should be appreciated that upon the additional elimination of the glucokinase and ethanol production mechanisms, mutant C exhibited a tighter coupling between lactate and biomass production.
Table I - Biomass and chemical yields for various gene knockout strategies identified by OptKnock. The reactions and corresponding enzymes for each knockout strategy are listed. The maximum biomass and corresponding chemical yields are provided on a basis of 10 mmol/hr glucose fed and 1 gDW of cells. The rightmost column provides the chemical yields for the same basis assuming a minimal redistribution of metabohc fluxes from the wild-type (undeleted) E. coli network (MOMA assumption). For the 1,3-propanediol case, glycerol secretion was disabled for both knockout strategies.
Succinate max Vjj„m min E∑(v„ - v) ' Biomass Succinate Succinate
ID Knockouts Enzyme (1/hr) (mmol hr) (mmol hr)
Wild "Complete network" 0.38 0.12
1 COA+PYR→ACCOA+FOR Pyruvate formate lyase
0.31 10.70 1.65
2 NADH+PYR<->■LAC+NAD Lactate dehydrogenase
1 COA + PYR -» ACCOA + FOR Pyruvate formate lyase
2 NADH + PYR «• LAC + NAD Lactate dehydrogenase 0.31 10.70 4.79
3 ACCOA + 2NADH<→ COA + ETH + 2NAD Acetaldehyde dehydrogenase
C 1 ADP + PEP → ATP + PYR Pyruvate kinase
2 ACTP + ADP AC + ATP or Acetate kinase
0.16 15.15 6.21 ACCOA + Pi «• ACTP + COA Phosphotransacetylase
3 GLC + PEP → G6P + PYR Phosphotransferase system
Lactate mOX V biomass min E-Σ(v0 - v) 2
Biomass Lactate Lactate
ID Knockouts Enzyme (1/hr) (mmol/hr) (mmol hr)
Wild "Complete network" 0.38
1 ACTP + ADP - AC + ATP or Acetate kinase ACCOA + Pi «• ACTP + COA Phosphotransacetylase 0.28 10.46 5.58
2 ACCOA + 2 NADH <→ COA + ETH + 2 NAD Acetaldehyde dehydrogenase
ACTP + ADP «*AC + ATP or Acetate kinase ACCOA + Pi +* ACTP + COA
0.13 18.00 0.19
2 ATP + F6P →ADP + FDP or Phosphofructoldnase FDP -W-T3P1 + T3P2 Fructose-l,6-bisphosphatate aldolase
C 1 ACTP + ADP <+ AC + ATP or Acetate kinase ACCOA + Pi ACTP + COA Phosphotransacetylase
2 ATP + F6P →ADP + FDP or Phosphofructoldnase
0.12 18.13 10.53 FDP -T3P1 +T3P2 Fτuctose-l,6-bisphosphatate aldolase
3 ACCOA + 2 NADH «• COA + ETH + 2 NAD Acetaldehyde dehydrogenase
4 GLC + ATP → G6P + PEP Glucokinase
1,3-Prop anediol maX V biomass min EE(v„ - v) 2
Biomass 1,3-PD 1,3-PD π> Knockouts Enzyme (1/hr) (mmol/hr) (mmol/hr)
Wild "Complete network" 1.06 0 0
A 1 FDP → F6P + Pi or Fructose-l,6-bisphosphatase FDP Η-T3P1 + T3P2 Fructose-l,6-bisphosphate aldolase
2 13PDG + ADP 3PG + ATP or Phosphoglycerate kinase 0.21 9.66 8.66 NAD + Pi+T3Pl <» 13PDG + NADH Glyceraldehyde-3-phosphate dehydrogenase
3 GL + NAD <» GLAL + NADH Aldehyde dehydrogenase
1 T3P1 «÷ T3P2 Triosphosphate isomerase
2 G6P + NADP <*D6PGL + NADPH or Glucose 6-phosphate-l-dehydrogenase D6PGL→D6PGC 6-Phosphogluconolactonase 0.29 9.67 9.54
3 DR5P →ACAL + T3P1 Deoxyribose-phosphate aldolase
4 GL + NAD - GLAL + NADH Aldehyde dehydrogenase _^ EXAMPLE 2 1,3 -Propanediol (PDO) Production In addition to devising optimum gene knockout strategies, OptKnock was used to design strains where gene additions were needed along with gene deletions such as in PDO production in E. coli. Although microbial 1,3-propanediol (PDO) production methods have been developed utilizing glycerol as the primary carbon source (Hartlep et al, 2002; Zhu et al., 2002), the production of 1,3-propanediol directly from glucose in a single microorganism has recently attracted considerable interest (Cameron et al., 1998; Biebl et al., 1999; Zeng and Biebl, 2002). Because wild-type E. coli lacks the pathway necessary for PDO production, the gene addition framework was first employed (Burgard and Maranas, 2001) to identify the additional reactions needed for producing PDO from glucose in E. coli. The gene addition framework identified a straightforward three-reaction pathway involving the conversion of glycerol-3-P to glycerol by glycerol phosphatase, followed by the conversion of glycerol to 1,3 propanediol by glycerol dehydratase and 1,3- propanediol oxidoreductase. These reactions were then added to the E. coli stoichiometric model and the OptKnock procedure was subsequently applied.
OptKnock revealed that there was neither a single nor a double deletion mutant with coupled PDO and biomass production. However, one triple and multiple quadruple knockout strategies that can couple PDO production with biomass production was identified. Two of these knockout strategies are shown in Table I. The results suggested that the removal of certain key functionalities from the E. coli network resulted in PDO overproducing mutants for growth on glucose. Specifically, Table I reveals that the removal of two glycolytic reactions along with an additional knockout preventing the degradation of glycerol yields a network capable of reaching 72% of the theoretical maximum yield of PDO at the maximum biomass yield. Note that the glyceraldehyde-3- phosphate dehydrogenase {gapA) knockout was used by DuPont in their PDO- overproducingE. coli strain (Nakamura, 2002). Mutant B revealed an alternative strategy, involving the removal of the triose phosphate isomerase (tpi) enzyme exhibiting a similar PDO yield and a 38% higher biomass yield. Interestingly, a yeast strain deficient in triose phosphate isomerase activity was recently reported to produce glycerol, a key precursor to PDO, at 80-90% of its maximum theoretical yield (Compagno et al., 1996). The flux distributions of the wild-type E. coli, mutant A, and mutant B networks that maximize the biomass yield are available in Figure 4. Not surprisingly, further conversion of glycerol to glyceraldehyde was disrupted in both mutants A and B. For mutant A, the removal of two reactions from the top and bottom parts of glycolysis resulted in a nearly complete inactivation of the pentose phosphate and glycolysis (with the exception of triose phosphate isomerase) pathways. To compensate, the Εntner-Doudoroff glycolysis pathway is activated to channel flux from glucose to pyruvate and glyceraldehyde-3-phosphate (GAP). GAP is then converted to glycerol which is subsequently converted to PDO. Energetic demands lost with the decrease in glycolytic fluxes from the wild-type E. coli network case, are now met by an increase in the TCA cycle fluxes. The knockouts suggested for mutant B redirect flux toward the production of PDO by a distinctly different mechanism. The removal of the initial pentose phosphate pathway reaction results in the complete flow of metabolic flux through the first steps of glycolysis. At the fructose bisphosphate aldolase junction, the flow is split into the two product metabolites: dihydroxyacetone-phosphate (DHAP) which is converted to PDO and GAP which continues through the second half of the glycolysis. The removal of the triose- phosphate isomerase reaction prevents any interconversion between DHAP and GAP. Interestingly, a fourth knockout is predicted to retain the coupling between biomass formation and chemical production. This knockout prevents the "leaking" of flux through a complex pathway involving 15 reactions that together convert ribose-5-phosphate (R5P) to acetate and GAP, thereby decoupling growth from chemical production.
Next, the envelope of allowable PDO production versus biomass yield is explored for the two mutants listed in Table I. The production limits of the mutants along with the original E. coli network, illustrated in Figure 5, reveal that the wild-type E. coli network has no "incentive" to produce PDO if the biomass yield is to be maximized. On the other hand, both mutants A and B have to produce significant amounts of PDO if any amount of biomass is to be formed given the reduced functionalities of the network following the gene removals. Mutant A, by avoiding the tpi knockout that essentially sets the ratio of biomass to PDO production, is characterized by a higher maximum theoretical yield of PDO. The above described results hinge on the use of glycerol as a key intermediate to PDO. Next, the possibility of utilizing an alternative to the glycerol conversion route for 1,3- propandediol production was explored.
Applicants identified a pathway in Chloroflexus aurantiacus involving a two-step NADPH-dependant reduction of malonyl-CoA to generate 3-hydroxypropionic acid (3- HP A) (Menendez et al., 1999; Hugler et al., 2002). 3-HPA could then be subsequently converted chemically to 1,3 propanediol given that there is no biological functionality to achieve this transformation. This pathway offers a key advantage over PDO production through the glycerol route because its initial step (acetyl-CoA carboxylase) is a carbon fixing reaction. Accordingly, the maximum theoretical yield of 3-HPA (1.79 mmol/mmol glucose) is considerably higher than for PDO production through the glycerol conversion route (1.34 mmol/mmol glucose). The application of the OptKnock framework upon the addition of the 3-HPA production pathway revealed that many more knockouts are required before biomass formation is coupled with 3-HPA production. One of the most interesting strategies involves nine knockouts yielding 3-HPA production at 91% of its theoretical maximum at optimal growth. The first three knockouts were relatively straightforward as they involved removal of competing acetate, lactate, and ethanol production mechanisms, hi addition, the Entner-Doudoroff pathway (either phosphogluconate dehydratase or 2- keto-3-deoxy-6-phosphogluconate aldolase), four respiration reactions (i.e., NADH dehydrogenase I, NADH dehydrogenase II, glycerol-3-ρhosphate dehydrogenase, and the succinate dehydrogenase complex), and an initial glycolyis step (i.e., phosphoglucose isomerase) are disrupted. This strategy resulted in a 3-HPA yield that, assuming the maximum biomass yield, is 69% higher than the previously identified mutants utilizing the glycerol conversion route.
EXAMPLE 3 Alternative Cellular Objective: Minimization of Metabohc Adjustment
All results described previously were obtained by invoking the maximization of biomass yield as the cellular objective that drives flux allocation. This hypothesis essentially assumes that the metabolic network could arbitrarily change and/or even rewire regulatory loops to maintain biomass yield maximality under changing environmental conditions (maximal response). Recent evidence suggests that this is sometimes achieved by the K-12 strain of E. coli after multiple cycles of growth selection (Ibarra et al., 2002). h this section, a contrasting hypothesis was examined (i.e., minimization of metabolic adjustment (MOMA) (Segre et al., 2002)) that assumed a myopic (minimal) response by the metabolic network upon gene deletions. Specifically, the MOMA hypothesis suggests that the metabolic network will attempt to remain as close as possible to the original steady state of the system rendered unreachable by the gene deletion(s). This hypothesis has been shown to provide a more accurate description of flux allocation immediately after a gene deletion event (Segre et al., 2002). Figure 6 pictorially shows the two differing new steady states predicted by the two hypotheses, respectively. For this study, the MOMA objective was utilized to predict the flux distributions in the mutant strains identified by OptKnock. The base case for the lactate and succinate simulations was assumed to be maximum biomass formation under anaerobic conditions, while the base case for the PDO simulations was maximum biomass formation under aerobic conditions. The results are shown in the last column of Table 1. In all cases, the suggested multiple gene knock-out strategy suggests only shghtly lower chemical production yields for the MOMA case compared to the maximum biomass hypothesis. This implies that the OptKnock results are fairly robust with respect to the choice of cellular objective.
The publications and other material used herein to illuminate the background of the invention or provide additional details respecting the practice, are herein incorporated by reference in their entirety. The present invention contemplates numerous variations, including variations in organisms, variations in cellular objectives, variations in bioengineering objectives, variations in types of optimization problems formed and solutions used.
These and/or other variations, modifications or alterations maybe made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
REFERENCES
Badarinarayana, V, Estep, PW, 3rd, Shendure, J, Edwards, J, Tavazoie, S, Lam, F, Church,
GM. 2001. Selection analyses of insertional mutants using subgenic-resolution arrays. Nat Biotechnol 19(11): 1060-5. Bard, JF. 1998. Practical bilevel optimization : algorithms and applications. Dordrecht ;
Boston, Kluwer Academic. Biebl, H, Menzel, K, Zeng, AP, Deckwer, WD. 1999. Microbial production of 1,3- propanediol. Appl Environ Microbiol 52: 289-297. Burgard, AP, Maranas, CD. 2001. Probing the performance limits of the Escherichia coli metabolic network subject to gene additions or deletions. Biotechnol Bioeng 74:
364-375. Burgard, AP, Maranas, CD. 2003. Optimization-based framework for inferring and testing hypothesized metabolic objective functions. Biotechnol Bioeng 82(6): 670-7. Burgard, AP, Vaidyaraman, S, Maranas, CD. 2001. Minimal Reaction Sets for Escherichia coli Metabolism under Different Growth Requirements and Uptake Environments.
Biotechnol Prog 17: 791-797. Cameron, DC, Altaras, NE, Hoffman, ML, Shaw, AJ. 1998. Metabolic engineering of propanediol pathways. Biotechnol Prog 14(1): 116-25. Compagno, C, Boschi, F, Ranzi, BM. 1996. Glycerol production in a triose phosphate isomerase deficient mutant of Saccharomyces cerevisiae. Biotechnol Prog 12(5):
591-5. Covert, MW, Palsson, BO. 2002. Transcriptional regulation in constraints-based metabolic models of Escherichia coli. J Biol Chem 277(31): 28058-64. Covert, MW, Schilling, CH, Palsson, BO. 2001. Regulation of gene expression in flux balance models of metabolism. J Theor Biol 213(1): 73-88.
Datta, R, Tsai, S, Bonsignore, P, Moon, S, Frank, JR. 1995. Technological and economic potential of poly(lactic acid) and lactic acid derivatives. FEMS Microbiol. Rev. 16:
221-231. Edwards, JS, Ibarra, RU, Palsson, BO. 2001. In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. Nat Biotechnol 19(2):
125-30. Edwards, JS, Palsson, BO. 2000. The Escherichia coh MG1655 in silico metabolic genotype: its definition, characteristics, and capabilities. Proc Natl Acad Sci U S A
97(10): 5528-33. Forster, J, Famili, I, Fu, PC, Palsson, B, Nielsen, J. 2003. Genome-scale reconstruction of the Saccharomyces cerevisiae metabolic network. Genome Research 13(2): 244-
253. Gupta, S, Clark, DP. 1989. Escherichia coh derivatives lacking both alcohol dehydrogenase and phosphotransacetylase grow anaerobically by lactate fermentation. J Bacteriol 171(7): 3650-5.
Hartlep, M, Hussmann, W, Prayitno, N, Meynial-Salles, I, Zeng, AP. 2002. Study of two- stage processes for the microbial production of 1,3-propanediol from glucose. Appl
Microbiol Biotechnol 60(1-2): 60-6. Hatzimanikatis, V, Emmerling, M, Sauer, U, Bailey, JE. 1998. Application of mathematical tools for metabolic design of microbial ethanol production.
Biotechnol Bioeng 58(2-3): 154-61. Heinrich, R, Rapoport, TA. 1974. A linear steady-state treatment of enzymatic chains. Eur.
J. Biochem. 41: 89-95. Hugler, M, Menendez, C, Schagger, H, Fuchs, G. 2002. Malonyl-coenzyme A reductase from Chloroflexus aurantiacus, a key enzyme of the 3-hydroxypropionate cycle for autotrophic CO(2) fixation. J Bacteriol 184(9): 2404-10.
Ibarra, RU, Edwards, JS, Palsson, BO. 2002. Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth. Nature 420(6912): 186-9. Ignizio, JP, Cavalier, TM. 1994. Linear programming. Englewood Cliffs, N.J., Prentice
Hall. Kacser, H, Burns, JA. 1973. The control of flux. Symp. Soc. Exp. Biol. 27: 65-104.
Kompala, DS, Ramkrishna, D, Tsao, GT. 1984. Cybernetic Modeling of Microbial Growth on Multiple Substrates. Biotechnol Bioeng 26(11): 1272-1281. Majewski, RA, Domach, MM. 1990. Simple constrained optimization view of acetate overflow in Escherichia coli. Biotechnol Bioeng 35: 732-738. Menendez, C, Bauer, Z, Huber, H, Gad'on, N, Stetter, KO, Fuchs, G. 1999. Presence of acetyl coenzyme A (CoA) carboxylase and propionyl-CoA carboxylase in autotrophic Crenarchaeota and indication for operation of a 3-hydroxypropionate cycle in autotrophic carbon fixation. J Bacteriol 181(4): 1088-98. Nakamura, CE. 2002. Production of 1,3-Propanediol by E. coli. presented at Metab Eng TV Conf: Tuscany, Italy.
Neidhardt, FC, Curtiss, R. 1996. Escherichia coli and Salmonella : cellular and molecular biology. Washington, D.C., ASM Press. Papin, JA, Price, ND, Wiback, SJ, Fell, DA, Palsson, B. 2003. Metabolic Pathways in the
Post-Genome Era. Trends Biochem Sci, accepted. Price, ND, Papin, JA, Schilling, CH, Palsson, B. 2003. Genome-scale Microbial hi Silico
Models: The Constraints-Based Approach. Trends Biotechnol, accepted. Ramakrishna, R, Edwards, JS, McCulloch, A, Palsson, BO. 2001. Flux-balance analysis of mitochondrial energy metabolism: consequences of systemic stoichiometric constraints. Am J Physiol Regul fritegr Comp Physiol 280(3): R695-704. Ramakrishna, R, Ramakrishna, D, Konopka, AE. 1996. Cybernetic Modeling of Growth in
Mixed, Substitutable Substrate Environments: Preferential and Simultaneous
Utilization. Biotechnol Bioeng 52: 141-151. Schilling, CH, Covert, MW, Famili, I, Church, GM, Edwards, JS, Palsson, BO. 2002.
Genome-scale metabolic model of Helicobacter pylori 26695. J Bacteriol 184(16): 4582-93.
Schilling, CH, Palsson, BO. 2000. Assessment of the metabolic capabilities of
Haemophilus influenzae Rd through a genome-scale pathway analysis. J Theor Biol
203(3): 249-83. Segre, D, Vitkup, D, Church, GM. 2002. Analysis of optimality in natural and perturbed metabolic networks. Proc Natl Acad Sci U S A 99(23): 15112-7.
Stephanopoulos, G, Aristidou, AA, Nielsen, J. 1998. Metabolic engineering : principles and methodologies. San Diego, Academic Press. Stols, L, Donnelly, MI. 1997. Production of succinic acid through overexpression of
NAD(+)-deρendent malic enzyme in an Escherichia coli mutant. Appl Environ Microbiol 63(7): 2695-701. Varma, A, Boesch, BW, Palsson, BO. 1993. Stoichiometric interpretation of Escherichia coli glucose catabolism under various oxygenation rates. Appl Environ Microbiol
59(8): 2465-73. Varma, A, Palsson, BO. 1993. Metabolic Capabilities of Escherichia coli: flL Optimal Growth Patterns. J. Theor. Biol. 165: 503-522.
Varma, A, Palsson, BO. 1994. Metabolic Flux Balancing: Basic Concepts, Scientific and
Practical Use. Bio/Technology 12: 994-998. Varner, J, Ramkrishna, D. 1999. Metabolic engineering from a cybernetic perspective. 1.
Theoretical preliminaries. Biotechnol Prog 15(3): 407-25. Zeikus, JG, Jain, MK, Elankovan, P. 1999. Biotechnology of succinate acid production and markets for derived industrial products. Appl Microbiol Biotechnol 51: 545-552. Zeng, AP, Biebl, H. 2002. Bulk chemicals from biotechnology: the case of 1,3-propanediol production and the new trends. Adv Biochem Eng Biotechnol 74: 239-59. Zhu, MM, Lawman, PD, Cameron, DC. 2002. Improving 1,3-propanediol production from glycerol in a metabolically engineered Escherichia coli by reducing accumulation of sn-glycerol-3 -phosphate. Biotechnol Prog 18(4): 694-9.

Claims

What is claimed is:
1. A method for determining candidates for gene deletions and additions using a model of a metabolic network associated with an organism, the model comprising a plurality of metabolic reactions defining metabolite relationships, the method comprising: selecting a bioengineering objective for the organism; selecting at least one cellular objective; forming an optimization problem that couples the at least one cellular objective with the bioengineering objective; and solving the optimization problem to yield at least one candidate.
2. The method of claim 1 further comprising modifying the organism with the candidate.
3. The method of claim 1 wherein the bioengineering objective is overproduction of a chemical.
4. The method of claim 1 wherein the bioengineering objective is underproduction of a chemical.
5. The method of claim 1 wherein the cellular objective is growth.
6. The method of claim 1 wherein the cellular objective is minimization of metabolic adjustment.
7. The method of claim 1 wherein the candidate is a candidate for gene deletion, and the optimization problem includes a binary value for specifying if reaction flux is active or inactive.
8. The method of claim 1 wherein the optimization problem is a bilevel optimization problem.
9. The method of claim 1 wherein the optimization problem is a mixed-integer optimization problem.
10. The method of claim 1 wherein the optimization problem includes at least one stoichiometric constraint.
11. The method of claim 1 wherein the optimization problem includes at least one chemical uptake constraint.
12. The method of claim 1 wherein the step of forming an optimization problem includes quantifying the cellular objective as an aggregate reaction flux.
13. The method of claim 1 further comprising evaluating performance limits of the metabolic network with the at least one candidate based on ability of the network to meet the at least one cellular objective.
14. The method of claim 1 wherein the cellular objective is selected from the group consisting of: maximizing a growth rate, maximizing ATP production, minimizing metabolic adjustment, minimizing nutrient uptake, minimizing redox production, minimizing a Euclidean norm, and combinations thereof.
15. The method of claim 1 wherein the bioengineering obj ective is overproduction of glycerol and at least one candidate is for gene deletion and comprising genes coding for the enzymes fructose- 1,6-bisphosphatase, fructose- 1,6-bisphosphatase aldolase, phosphoglycerate kinase, glyceraldehydes-3-phosphate dehydrogenase, phosphoenolpyruvate synthase, NADH dehydrogenase I, phosphogluconate dehydratase, 2- keto-3-deoxy-6-phosphofluconate aldolase, triosphosphate isomerase, glucose 6-phosphate- 1 -dehydrogenase, 6-phosphogluconolactonase, deoxyribose-phosphate aldolase, aldehyde dehydrogenase, or combinations thereof.
16. The method of claim 1 wherein the bioengineering objective is overproduction of 1,3-propanediol and at least one candidate is for gene deletion and comprising genes coding for the enzymes fructose- 1,6-bisphosphatase, fructose-l,6-bisphosphatase aldolase, phosphoglycerate kinase, glyceraldehyde-3 -phosphate dehyrogenase, triosphosphate isomerase, glucose 6-phosphate-l -dehydrogenase, 6-phosphogluconolactonase, deoxyribose-phosphate aldolase, aldehyde dehydrogenase, or combinations thereof.
17. The method of claim 1 wherein the bioengineering objective is overproduction of succinate and at least one candidate is for gene deletion and comprising genes coding for the enzymes pyruvate formate lyase, acetaldehyde dehydrogenase, pyruvate kinase, FOF1- ATPase, NADH dehydrogenase I, fumarase, D-Lactate dehydrogenase, pyridine nucleotide transhydrogenase, phosphotransacetylase, acetate kinase, phosphotransferase, or combinations thereof.
18. The method of claim 1 wherein the bioengineering obj ective is overproduction of lactate and at least one candidate is for gene deletion and comprising genes coding for the enzymes phosphotransacetylase, acetate kinase, phosphofructokinase, fructose-1,6- bisphosphatase aldolase, triosphosphate isomerase, acetaldehyde dehyrogenase, glucokinase, or combinations thereof.
19. A computer-based method for determining candidates for gene deletions and additions using a model of a metabolic network associated with an organism, the model comprising a plurality of metabolic reactions defining metabolite relationships, the method comprising: inputting at least one bioengineering objective; receiving as input as least one cellular objective; forming an optimization that quantifies the cellular objective as an aggregate reaction flux and couples the at least one cellular objective with the bioengineering objective; solving the optimization problem to yield at least one candidate; and outputting the at least one candidate.
PCT/US2003/021598 2002-07-10 2003-07-09 Method for determining gene knockout strategies WO2004018621A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03792962A EP1532516A4 (en) 2002-07-10 2003-07-09 Method for determining gene knockout strategies
JP2005501742A JP4418793B2 (en) 2002-07-10 2003-07-09 How to determine a gene knockout strategy
CA002491753A CA2491753A1 (en) 2002-07-10 2003-07-09 Method for determining gene knockout strategies
AU2003256480A AU2003256480B2 (en) 2002-07-10 2003-07-09 Method for determining gene knockout strategies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39576302P 2002-07-10 2002-07-10
US60/395,763 2002-07-10
US41751102P 2002-10-09 2002-10-09
US60/417,511 2002-10-09
US44493303P 2003-02-03 2003-02-03
US60/444,933 2003-02-03

Publications (2)

Publication Number Publication Date
WO2004018621A2 true WO2004018621A2 (en) 2004-03-04
WO2004018621A3 WO2004018621A3 (en) 2004-09-30

Family

ID=31950535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021598 WO2004018621A2 (en) 2002-07-10 2003-07-09 Method for determining gene knockout strategies

Country Status (6)

Country Link
US (2) US8027821B2 (en)
EP (1) EP1532516A4 (en)
JP (2) JP4418793B2 (en)
AU (2) AU2003256480B2 (en)
CA (1) CA2491753A1 (en)
WO (1) WO2004018621A2 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023493A1 (en) * 2007-08-10 2009-02-19 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
US7711490B2 (en) 2001-01-10 2010-05-04 The Penn State Research Foundation Method and system for modeling cellular metabolism
US7826975B2 (en) 2002-07-10 2010-11-02 The Penn State Research Foundation Method for redesign of microbial production systems
JP4771437B2 (en) * 2004-08-27 2011-09-14 ライス ユニバーシティー Mutant E. with increased succinic acid production E. coli strain
US8027821B2 (en) 2002-07-10 2011-09-27 The Penn State Research Foundation Method for determining gene knockouts
EP2400027A1 (en) * 2006-10-31 2011-12-28 Metabolic Explorer Process for the biological production of 1,3-propanediol from glycerol with high yield
JP2012104129A (en) * 2011-12-02 2012-05-31 Penn State Res Found:The Method for redesigning microbiological production system
JP2013505727A (en) * 2009-09-27 2013-02-21 オーピーエックス バイオテクノロジーズ, インコーポレイテッド Process for producing 3-hydroxypropionic acid and other products
CN103146740A (en) * 2013-03-06 2013-06-12 中国科学院南海海洋研究所 Engineering bacteria for producing 1,3-propylene glycol and method for constructing same
US8652816B2 (en) 2007-12-04 2014-02-18 Opx Biotechnologies, Inc. Compositions and methods for 3-hydroxypropionate bio-production from biomass
US8809027B1 (en) 2009-09-27 2014-08-19 Opx Biotechnologies, Inc. Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase
US9169486B2 (en) 2011-06-22 2015-10-27 Genomatica, Inc. Microorganisms for producing butadiene and methods related thereto
US9512057B2 (en) 2013-03-15 2016-12-06 Cargill, Incorporated 3-hydroxypropionic acid compositions
US9677045B2 (en) 2012-06-04 2017-06-13 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US9988656B2 (en) 2009-11-25 2018-06-05 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US10047383B2 (en) 2013-03-15 2018-08-14 Cargill, Incorporated Bioproduction of chemicals
US10208320B2 (en) 2008-03-05 2019-02-19 Genomatica, Inc. Primary alcohol producing organisms
US10273508B2 (en) 2009-06-04 2019-04-30 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods
US10337038B2 (en) 2013-07-19 2019-07-02 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10465213B2 (en) 2012-08-10 2019-11-05 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10494654B2 (en) 2014-09-02 2019-12-03 Cargill, Incorporated Production of fatty acids esters
US11345938B2 (en) 2017-02-02 2022-05-31 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives
US11371046B2 (en) 2007-03-16 2022-06-28 Genomatica, Inc. Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147229A2 (en) * 1999-02-02 2001-10-24 Bernhard O. Palsson Methods for identifying drug targets based on genomic sequence data
US7127379B2 (en) * 2001-01-31 2006-10-24 The Regents Of The University Of California Method for the evolutionary design of biochemical reaction networks
CA2439260C (en) * 2001-03-01 2012-10-23 The Regents Of The University Of California Models and methods for determining systemic properties of regulated reaction networks
US7751981B2 (en) 2001-10-26 2010-07-06 The Regents Of The University Of California Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism
US20030224363A1 (en) * 2002-03-19 2003-12-04 Park Sung M. Compositions and methods for modeling bacillus subtilis metabolism
AU2003222128A1 (en) * 2002-03-29 2003-10-13 Genomatica, Inc. Human metabolic models and methods
US8949032B2 (en) * 2002-03-29 2015-02-03 Genomatica, Inc. Multicellular metabolic models and methods
CA2500761C (en) * 2002-10-15 2012-11-20 Bernhard O. Palsson Methods and systems to identify operational reaction pathways
US7869957B2 (en) * 2002-10-15 2011-01-11 The Regents Of The University Of California Methods and systems to identify operational reaction pathways
US20060052942A1 (en) * 2004-05-21 2006-03-09 Shuo-Huan Hsu Integrated knowledge-based reverse engineering of metabolic pathways
KR100630836B1 (en) * 2005-04-08 2006-10-02 한국과학기술원 - Method for Improving a Strain Based on In-Silico Analysis
KR100655495B1 (en) * 2005-07-11 2006-12-08 한국과학기술원 - Method of In-silico Improvement of Organisms Using the Flux Sum of Metabolites
US20070111294A1 (en) * 2005-09-09 2007-05-17 Genomatica, Inc. Methods and organisms for the growth-coupled production of succinate
EP1924703A1 (en) * 2005-09-15 2008-05-28 Korea Advanced Institute of Science and Technology Method for improving organisms using flux scanning based on enforced objective flux
EP2002009A4 (en) 2006-03-31 2012-01-04 Rice University Anaerobic fermentation of glycerol
US8673601B2 (en) * 2007-01-22 2014-03-18 Genomatica, Inc. Methods and organisms for growth-coupled production of 3-hydroxypropionic acid
CA2679987A1 (en) * 2007-03-23 2008-10-02 Metabolic Explorer Metabolically engineered microorganism useful for the production of 1,2-propanediol
US20090023182A1 (en) * 2007-07-18 2009-01-22 Schilling Christophe H Complementary metabolizing organisms and methods of making same
AU2008307381B2 (en) 2007-08-10 2014-02-20 Genomatica, Inc. Methods for the synthesis of acrylic acid and derivatives from fumaric acid
CA2712779C (en) * 2008-01-22 2021-03-16 Genomatica, Inc. Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol
CN103555643B (en) 2008-03-27 2016-08-10 基因组股份公司 For producing the microorganism of adipic acid and other compounds
CA2722680A1 (en) 2008-05-01 2009-11-05 Genomatica, Inc. Microorganisms for the production of methacrylic acid
WO2009155382A1 (en) 2008-06-17 2009-12-23 Genomatica, Inc. Microorganisms and methods for the biosynthesis of fumarate, malate, and acrylate
US20100021978A1 (en) * 2008-07-23 2010-01-28 Genomatica, Inc. Methods and organisms for production of 3-hydroxypropionic acid
EP3514242A3 (en) * 2008-09-10 2019-08-28 Genomatica, Inc. Microrganisms for the production of 1,4-butanediol
WO2010031083A2 (en) * 2008-09-15 2010-03-18 Opx Biotechnologies, Inc. Methods, systems and compositions related to reduction of conversions of microbially produced 3-hydroxypropionic acid (3-hp) to aldehyde metabolites
US20100184173A1 (en) * 2008-11-14 2010-07-22 Genomatica, Inc. Microorganisms for the production of methyl ethyl ketone and 2-butanol
AU2009327490A1 (en) * 2008-12-16 2011-07-28 Genomatica, Inc. Microorganisms and methods for conversion of syngas and other carbon sources to useful products
CN106119113A (en) 2009-04-30 2016-11-16 基因组股份公司 For producing the biology of 1,3 butanediols
WO2010127303A1 (en) 2009-04-30 2010-11-04 Genomatica, Inc. Organisms for the production of isopropanol, n-butanol, and isobutanol
EP2427544B1 (en) 2009-05-07 2019-07-17 Genomatica, Inc. Microorganisms and methods for the biosynthesis of adipate, hexamethylenediamine and 6-aminocaproic acid
JP2012526561A (en) * 2009-05-15 2012-11-01 ゲノマチカ, インク. Organisms for the production of cyclohexanone
JP6133599B2 (en) * 2009-06-04 2017-05-24 ゲノマチカ, インク. Method for separating components of fermentation broth
WO2010144746A2 (en) * 2009-06-10 2010-12-16 Genomatica, Inc. Microorganisms and methods for carbon-efficient biosynthesis of mek and 2-butanol
EP3190174A1 (en) 2009-08-05 2017-07-12 Genomatica, Inc. Semi-synthetic terephthalic acid via microorganisms that produce muconic acid
BR112012005296A2 (en) 2009-09-09 2019-01-15 Genomatica Inc microorganisms and methods for the co-production of isopropanol with primary alcohols, dios and acids.
JP2013507145A (en) 2009-10-13 2013-03-04 ゲノマチカ, インク. Microorganisms and related methods for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-CoA, putrescine and related compounds
KR20120088753A (en) * 2009-10-23 2012-08-08 게노마티카 인코포레이티드 Microorganisms for the production of aniline
CA2781400A1 (en) * 2009-11-20 2011-05-26 Opx Biotechnologies, Inc. Production of an organic acid and/or related chemicals
WO2011071682A1 (en) 2009-12-10 2011-06-16 Genomatica, Inc. Methods and organisms for converting synthesis gas or other gaseous carbon sources and methanol to 1,3-butanediol
SG182686A1 (en) 2010-01-29 2012-08-30 Genomatica Inc Microorganisms and methods for the biosynthesis of p-toluate and terephthalate
US8637286B2 (en) * 2010-02-23 2014-01-28 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) * 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
US9023636B2 (en) 2010-04-30 2015-05-05 Genomatica, Inc. Microorganisms and methods for the biosynthesis of propylene
KR20180005263A (en) 2010-05-05 2018-01-15 게노마티카 인코포레이티드 Microorganisms and methods for the biosynthsis of butadiene
CA2806230A1 (en) 2010-07-26 2012-02-09 Genomatica, Inc. Microorganisms and methods for the biosynthesis of aromatics, 2,4-pentadienoate and 1,3-butadiene
AU2012212118B2 (en) 2011-02-02 2015-11-12 Genomatica, Inc. Microorganisms and methods for the biosynthesis of butadiene
US8617862B2 (en) 2011-06-22 2013-12-31 Genomatica, Inc. Microorganisms for producing propylene and methods related thereto
WO2013028519A1 (en) 2011-08-19 2013-02-28 Genomatica, Inc. Microorganisms and methods for producing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol and related alcohols
KR20140070605A (en) 2011-09-16 2014-06-10 게노마티카 인코포레이티드 Microorganisms and methods for producing alkenes
MY197970A (en) 2011-11-02 2023-07-25 Genomatica Inc Microorganisms and methods for the production of caprolactone
WO2013109865A2 (en) 2012-01-20 2013-07-25 Genomatica, Inc. Microorganisms and processes for producing terephthalic acid and its salts
US9657316B2 (en) 2012-08-27 2017-05-23 Genomatica, Inc. Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 1,4-butanediol related thereto
EP2909325A4 (en) 2012-10-22 2016-05-25 Genomatica Inc Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing succinate related thereto
WO2014071286A1 (en) 2012-11-05 2014-05-08 Genomatica, Inc. Microorganisms for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 1,2-propanediol
WO2014071289A1 (en) 2012-11-05 2014-05-08 Genomatica, Inc. Microorganisms for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 3-hydroxyisobutyrate
WO2014076232A2 (en) 2012-11-19 2014-05-22 Novozymes A/S Isopropanol production by recombinant hosts using an hmg-coa intermediate
JP2015536669A (en) 2012-11-30 2015-12-24 ノボザイムス,インコーポレイティド Production of 3-hydroxypropionic acid by recombinant yeast
TWI716752B (en) 2012-12-17 2021-01-21 美商奇諾麥提卡公司 Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing adipate, 6-aminocaproate, hexamethylenediamine or caprolactam related thereto
EP2971021A4 (en) 2013-03-15 2016-12-21 Genomatica Inc Microorganisms and methods for producing butadiene and related compounds by formate assimilation
MY187966A (en) 2013-04-26 2021-11-02 Genomatica Inc Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
JP6320697B2 (en) * 2013-07-29 2018-05-09 三井造船株式会社 Acetic acid non-producing and lactic acid producing strains of Morella bacteria
DK3027733T3 (en) 2013-07-31 2018-12-10 Novozymes As Preparation of 3-Hydroxypropionic Acid in Recombinant Yeast Expressing an Insect Aspartate-1 Decarboxylase
WO2015077752A1 (en) 2013-11-25 2015-05-28 Genomatica, Inc. Methods for enhancing microbial production of specific length fatty alcohols in the presence of methanol
PL3077501T3 (en) 2013-12-03 2022-01-31 Genomatica, Inc. Microorganisms and methods for improving product yields on methanol using acetyl-coa synthesis
JP6580051B2 (en) * 2014-02-07 2019-09-25 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se Improved microorganisms for succinic acid production
WO2016007365A1 (en) 2014-07-11 2016-01-14 Genomatica, Inc. Microorganisms and methods for the production of butadiene using acetyl-coa
WO2016100910A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Recombinant host cells for the production of 3-hydroxypropionic acid
DK3262161T3 (en) 2015-02-27 2021-09-13 Novozymes As Recombinant host cells for the production of 3-hydroxypropionic acid
EP3341475A1 (en) 2015-08-24 2018-07-04 Novozymes A/S Beta-alanine aminotransferases for the production of 3-hydroxypropionic acid
EP3267345A1 (en) * 2016-07-06 2018-01-10 European Molecular Biology Laboratory Methods for adaptive laboratory evolution
BR112019013007A2 (en) 2016-12-21 2019-10-08 Creatus Biosciences Inc unnatural microbial organism, method of producing a bioderivated compound, bioderivated compound and composition
BR112019013005A2 (en) 2016-12-21 2019-10-08 Creatus Biosciences Inc metschnikowia species isolated, method for producing xylitol, bioderivated xylitol and composition
CN110691847A (en) 2017-03-31 2020-01-14 基因组股份公司 3-hydroxybutyryl-CoA dehydrogenase variants and methods of use
EP3601546A1 (en) 2017-03-31 2020-02-05 Genomatica, Inc. Aldehyde dehydrogenase variants and methods of use
US20210079334A1 (en) 2018-01-30 2021-03-18 Genomatica, Inc. Fermentation systems and methods with substantially uniform volumetric uptake rate of a reactive gaseous component
KR20210068489A (en) 2018-09-26 2021-06-09 게노마티카 인코포레이티드 Aldehyde dehydrogenase variants and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012939A1 (en) * 1999-02-02 2002-01-31 Bernhard Palsson Methods for identifying drug targets based on genomic sequence data
WO2002055995A2 (en) * 2001-01-10 2002-07-18 Penn State Res Found Method and system for modeling cellular metabolism
US20020142321A1 (en) * 2001-01-31 2002-10-03 Palsson Bernhard O. Method for the evolutionary design of biochemical reaction networks

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520103A (en) 1982-10-27 1985-05-28 Amgen Microbial production of indigo
WO1998018814A1 (en) 1996-10-28 1998-05-07 Cumulative Inquiry, Inc. Nucleic acid-level analysis of protein structure
US6117108A (en) 1997-08-20 2000-09-12 Braun Melsungen Ag Spring clip safety IV catheter
AU1199000A (en) 1998-09-29 2000-04-17 Maxygen, Inc. Shuffling of codon altered genes
AU2415200A (en) 1999-01-18 2000-08-01 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
JP2000268018A (en) 1999-03-16 2000-09-29 Nippon Telegr & Teleph Corp <Ntt> Device and method for multipurpose optimization and storage medium storing multipurpose optimization program
EP1283877A2 (en) 2000-05-23 2003-02-19 California Institute Of Technology Gene recombination and hybrid protein development
US20030073092A1 (en) 2000-11-10 2003-04-17 Maranas Costas D. Modeling framework for predicting the number, type, and distribution of crossovers in directed evolution experiments
AU2003256480B2 (en) * 2002-07-10 2008-03-06 The Penn State Research Foundation Method for determining gene knockout strategies
US7826975B2 (en) * 2002-07-10 2010-11-02 The Penn State Research Foundation Method for redesign of microbial production systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012939A1 (en) * 1999-02-02 2002-01-31 Bernhard Palsson Methods for identifying drug targets based on genomic sequence data
WO2002055995A2 (en) * 2001-01-10 2002-07-18 Penn State Res Found Method and system for modeling cellular metabolism
US20020142321A1 (en) * 2001-01-31 2002-10-03 Palsson Bernhard O. Method for the evolutionary design of biochemical reaction networks

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURGARD A.P. ET AL: 'Minimal Reaction Sets for Escherichia coli Metabolism under Different Growth Requirements and Uptake Environments' BIOTECHNOLOGY PROGRESS vol. 17, no. 5, 14 September 2001, pages 791 - 797, XP002978705 *
BURGARD A.P. ET AL: 'Probing the performance limits of the escherichia coli metabolic network subject to gene additions or deletions' BIOTECHNOLOGY AND BIOENGINEERING vol. 74, no. 5, 05 September 2001, pages 364 - 375, XP002965719 *
See also references of EP1532516A2 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7711490B2 (en) 2001-01-10 2010-05-04 The Penn State Research Foundation Method and system for modeling cellular metabolism
US8086414B2 (en) 2001-01-10 2011-12-27 The Penn State Research Foundation Method and system for modeling cellular metabolism
US7826975B2 (en) 2002-07-10 2010-11-02 The Penn State Research Foundation Method for redesign of microbial production systems
US8027821B2 (en) 2002-07-10 2011-09-27 The Penn State Research Foundation Method for determining gene knockouts
JP4771437B2 (en) * 2004-08-27 2011-09-14 ライス ユニバーシティー Mutant E. with increased succinic acid production E. coli strain
EP2400027A1 (en) * 2006-10-31 2011-12-28 Metabolic Explorer Process for the biological production of 1,3-propanediol from glycerol with high yield
US11371046B2 (en) 2007-03-16 2022-06-28 Genomatica, Inc. Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors
EP2679685A1 (en) * 2007-08-10 2014-01-01 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
EP2679684A1 (en) * 2007-08-10 2014-01-01 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
EP2679676A1 (en) * 2007-08-10 2014-01-01 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
WO2009023493A1 (en) * 2007-08-10 2009-02-19 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
US8652816B2 (en) 2007-12-04 2014-02-18 Opx Biotechnologies, Inc. Compositions and methods for 3-hydroxypropionate bio-production from biomass
US11613767B2 (en) 2008-03-05 2023-03-28 Genomatica, Inc. Primary alcohol producing organisms
US10208320B2 (en) 2008-03-05 2019-02-19 Genomatica, Inc. Primary alcohol producing organisms
US11401534B2 (en) 2009-06-04 2022-08-02 Genomatica, Inc. Microorganisms for the production of 1,4- butanediol and related methods
US10273508B2 (en) 2009-06-04 2019-04-30 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods
US9428778B2 (en) 2009-09-27 2016-08-30 Cargill, Incorporated Method for producing 3-hydroxypropionic acid and other products
US10100342B2 (en) 2009-09-27 2018-10-16 Cargill, Incorporated Method for producing 3-hydroxypropionic acid and other products
JP2016036346A (en) * 2009-09-27 2016-03-22 オーピーエックス バイオテクノロジーズ, インコーポレイテッド Method for producing 3-hydroxypropionic acid and other products
US9388419B2 (en) 2009-09-27 2016-07-12 Cargill, Incorporated Methods for producing 3-hydroxypropionic acid and other products
US8883464B2 (en) 2009-09-27 2014-11-11 Opx Biotechnologies, Inc. Methods for producing 3-hydroxypropionic acid and other products
JP2013505727A (en) * 2009-09-27 2013-02-21 オーピーエックス バイオテクノロジーズ, インコーポレイテッド Process for producing 3-hydroxypropionic acid and other products
US8809027B1 (en) 2009-09-27 2014-08-19 Opx Biotechnologies, Inc. Genetically modified organisms for increased microbial production of 3-hydroxypropionic acid involving an oxaloacetate alpha-decarboxylase
US9988656B2 (en) 2009-11-25 2018-06-05 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US10662451B2 (en) 2009-11-25 2020-05-26 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US10006055B2 (en) 2011-06-22 2018-06-26 Genomatica, Inc. Microorganisms for producing butadiene and methods related thereto
US9169486B2 (en) 2011-06-22 2015-10-27 Genomatica, Inc. Microorganisms for producing butadiene and methods related thereto
JP2012104129A (en) * 2011-12-02 2012-05-31 Penn State Res Found:The Method for redesigning microbiological production system
US11932845B2 (en) 2012-06-04 2024-03-19 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US9677045B2 (en) 2012-06-04 2017-06-13 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US11085015B2 (en) 2012-06-04 2021-08-10 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
US10465213B2 (en) 2012-08-10 2019-11-05 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
CN103146740B (en) * 2013-03-06 2014-08-20 中国科学院南海海洋研究所 Engineering bacteria for producing 1,3-propylene glycol and method for constructing same
CN103146740A (en) * 2013-03-06 2013-06-12 中国科学院南海海洋研究所 Engineering bacteria for producing 1,3-propylene glycol and method for constructing same
US10155937B2 (en) 2013-03-15 2018-12-18 Cargill, Incorporated Acetyl-CoA carboxylases
US10815473B2 (en) 2013-03-15 2020-10-27 Cargill, Incorporated Acetyl-CoA carboxylases
US10047383B2 (en) 2013-03-15 2018-08-14 Cargill, Incorporated Bioproduction of chemicals
US9512057B2 (en) 2013-03-15 2016-12-06 Cargill, Incorporated 3-hydroxypropionic acid compositions
US10337038B2 (en) 2013-07-19 2019-07-02 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
US10494654B2 (en) 2014-09-02 2019-12-03 Cargill, Incorporated Production of fatty acids esters
US11345938B2 (en) 2017-02-02 2022-05-31 Cargill, Incorporated Genetically modified cells that produce C6-C10 fatty acid derivatives

Also Published As

Publication number Publication date
EP1532516A2 (en) 2005-05-25
AU2003256480A1 (en) 2004-03-11
US8027821B2 (en) 2011-09-27
CA2491753A1 (en) 2004-03-04
EP1532516A4 (en) 2007-05-23
AU2008202455A1 (en) 2008-06-26
AU2003256480B2 (en) 2008-03-06
JP4418793B2 (en) 2010-02-24
US20040009466A1 (en) 2004-01-15
JP2009225808A (en) 2009-10-08
WO2004018621A3 (en) 2004-09-30
JP2005532826A (en) 2005-11-04
US8457941B2 (en) 2013-06-04
US20110301930A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
AU2003256480B2 (en) Method for determining gene knockout strategies
Burgard et al. Optknock: a bilevel programming framework for identifying gene knockout strategies for microbial strain optimization
US8108152B2 (en) Method for redesign of microbial production systems
Orth et al. Reconstruction and use of microbial metabolic networks: the core Escherichia coli metabolic model as an educational guide
Edwards et al. Robustness analysis of the escherichiacoli metabolic network
Kim et al. RELATCH: relative optimality in metabolic networks explains robust metabolic and regulatory responses to perturbations
Yang et al. EMILiO: a fast algorithm for genome-scale strain design
Förster et al. Genome-scale reconstruction of the Saccharomyces cerevisiae metabolic network
Schuetz et al. Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coli
Matsuoka et al. Current status and future perspectives of kinetic modeling for the cell metabolism with incorporation of the metabolic regulation mechanism
US9037445B2 (en) Flux balance analysis with molecular crowding
US7869957B2 (en) Methods and systems to identify operational reaction pathways
Lee et al. Genome-scale metabolic network reconstruction and in silico flux analysis of the thermophilic bacterium Thermus thermophilus HB27
Mol et al. Genome-scale metabolic modeling of P. thermoglucosidasius NCIMB 11955 reveals metabolic bottlenecks in anaerobic metabolism
Boecker et al. Deciphering the physiological response of Escherichia coli under high ATP demand
Jiang et al. Optdesign: Identifying optimum design strategies in strain engineering for biochemical production
Hu et al. Comparative study of two Saccharomyces cerevisiae strains with kinetic models at genome-scale
Apaydin et al. Robust mutant strain design by pessimistic optimization
AU2004322970B2 (en) Method for redesign of microbial production systems
Romeo et al. Glycolysis and flux control
Alter et al. Protein allocation and enzymatic constraints explain Escherichia coli wildtype and mutant phenotypes
Orth Systems biology analysis of Escherichia coli for discovery and metabolic engineering
Bergdahl et al. Genome‐scale models
JP2012104129A (en) Method for redesigning microbiological production system
Dinh Data-Integrated and Model-Driven Analysis of Yeast Metabolism and Resource Allocation at Genome-Scale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003256480

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005501742

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003792962

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2491753

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2003792962

Country of ref document: EP